1. Home
  2. JAGX vs EOCN Comparison

JAGX vs EOCN Comparison

Compare JAGX & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.38

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$2.96

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JAGX
EOCN
Founded
2013
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
3.6M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
JAGX
EOCN
Price
$2.38
$2.96
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 2.0M
6.4K
Earning Date
11-16-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.42
N/A
EPS
N/A
★ N/A
Revenue
★ $11,511,000.00
N/A
Revenue This Year
$77.78
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.20
$2.33
52 Week High
$41.53
$3.80

Technical Indicators

Market Signals
Indicator
JAGX
EOCN
Relative Strength Index (RSI) 45.70 47.58
Support Level $2.12 $3.12
Resistance Level $3.07 $3.80
Average True Range (ATR) 0.52 0.28
MACD -0.40 -0.01
Stochastic Oscillator 10.58 63.08

Price Performance

Historical Comparison
JAGX
EOCN

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Share on Social Networks: